BioNTech AG announced it has completed a USD 270 million Series A round of financing. The Company previously completed a seed round fundraising in 2008 concurrent with its founding. The Series A round was led by the Redmile Group and joined by Janus Henderson Investors, Invus, Fidelity Management & Research Company and several European family offices. The Struengmann Family Office, an existing investor in BioNTech, also participated in the capital raise. BioNTech will use the capital to further advance its clinical pipeline of individualized immunotherapies covering a number of new approaches including mRNA and CAR-T /T-Cell receptors for the treatment of cancer and other diseases with high medical need. Its corporate partnerships include collaborations with Genentech, a member of the Roche Group, Eli Lilly and Company, Sanofi, Genmab and Bayer Animal Health.